AI-driven small-molecule drug discovery for oncology
| Date | Round | Amount |
|---|---|---|
| May 2022 | Funding round Oxford Drug Design, an Oxford-based AI drug discovery biotech, raised GBP2.2M from existing investors including ACF Investors, o2h Ventures and R42 Group. | $2.8M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.